New combo therapy aims to stop aggressive kidney cancer from coming back
NCT ID NCT06210490
Summary
This study is testing if a drug called disitamab vedotin, given along with radiation therapy, can help prevent cancer from returning in patients who have had surgery for a specific type of upper urinary tract cancer (UTUC). The trial will enroll 60 patients whose cancer has a marker called HER2 and who are at high risk of the cancer coming back. One group will receive the new drug-radiation combination for 6 months, while another group will be closely monitored without this specific treatment, to compare outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER URINARY TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.